Company Filing History:
Years Active: 2020-2024
Title: Göran Alderborn: Innovator in Modified Release Compositions
Introduction
Göran Alderborn is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of modified release compositions for the treatment of obesity and related metabolic disorders. With a total of 2 patents to his name, Alderborn's work is recognized for its innovative approach to drug delivery.
Latest Patents
Alderborn's latest patents focus on a modified-release composition that combines orlistat and acarbose. This composition is designed to have distinct parts with varying release patterns. The first part, G1, comprises from about 5 to about 70% w/w of the total dose of acarbose. The second part, G2A, includes from about 30 to about 95% w/w of the total dose of acarbose. The third part, G2B, consists of from about 10 to about 90% w/w of the total dose of orlistat. Finally, the fourth part, G3, contains from about 10 to about 80% w/w of the total dose of orlistat. The total concentration of acarbose and orlistat in the composition is 100% w/w.
Career Highlights
Göran Alderborn is associated with Empros Pharma AB, where he continues to advance his research and development efforts. His work has been instrumental in creating effective pharmaceutical solutions that address obesity and metabolic disorders.
Collaborations
Alderborn collaborates with notable colleagues such as Anders Forslund and Ulf Holmbäck. Their combined expertise contributes to the innovative projects at Empros Pharma AB.
Conclusion
Göran Alderborn's contributions to the field of pharmaceutical formulations highlight his role as an innovator in modified release compositions. His work continues to impact the treatment of obesity and related metabolic disorders, showcasing the importance of innovation in healthcare.